| MeSH term | MeSH ID | Detail |
|---|---|---|
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Ecthyma, Contagious | D004474 | 1 associated lipids |
| Priapism | D011317 | 1 associated lipids |
| Vulvar Lichen Sclerosus | D007724 | 1 associated lipids |
| Mediastinal Diseases | D008477 | 1 associated lipids |
| Hypophosphatemia | D017674 | 1 associated lipids |
| Leukemia, Myeloid, Chronic-Phase | D015466 | 1 associated lipids |
| Myelinolysis, Central Pontine | D017590 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Siekierka JJ et al. | Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. | 1991 | Transplant. Proc. | pmid:1721256 |
| Morris RE | In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. | 1991 | Transplant. Proc. | pmid:1721257 |
| Loréal O et al. | FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. | 1991 | Transplant. Proc. | pmid:1721289 |
| Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
| Green M et al. | Infectious complications of pediatric liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721352 |
| Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
| Torre-Cisneros J et al. | The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721353 |
| Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
| Tauxe WN et al. | A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. | 1991 | Transplant. Proc. | pmid:1721386 |
| Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
| Wiederrecht G et al. | FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1704127 |
| Fabrega AJ et al. | FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1721447 |
| Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
| Palaszynski EW et al. | Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. | 1991 | Clin. Biochem. | pmid:1711940 |
| Shiraki K et al. | Effect of FK-506 on replication of human cytomegalovirus in vitro. | 1991 | J. Antibiot. | pmid:1712008 |
| Katz IA et al. | Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. | 1991 | Transplantation | pmid:1716801 |
| Baumann G et al. | Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. | 1991 | New Biol. | pmid:1715185 |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| Mieles L et al. | Oral glucose tolerance test in liver recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689894 |
| Alessiani M et al. | Infections with FK 506 immunosuppression: preliminary results with primary therapy. | 1990 | Transplant. Proc. | pmid:1689895 |
| Staschak S et al. | A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. | 1990 | Transplant. Proc. | pmid:1689896 |
| Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. | 1990 | Transplant. Proc. | pmid:1689897 | |
| Cadoff EM et al. | Assay of FK 506 in plasma. | 1990 | Transplant. Proc. | pmid:1689898 |
| Venkataramanan R et al. | Pharmacokinetics of FK 506: preclinical and clinical studies. | 1990 | Transplant. Proc. | pmid:1689899 |
| Jain AB et al. | Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. | 1990 | Transplant. Proc. | pmid:1689900 |
| Fung JJ et al. | Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. | 1990 | Transplant. Proc. | pmid:1689901 |
| Zeevi A et al. | Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. | 1990 | Transplant. Proc. | pmid:1689902 |
| Thomas FT et al. | Comparative efficacy of immunosuppressive drugs in xenografting. | 1990 | Transplant. Proc. | pmid:1693452 |
| Harrison RK and Stein RL | Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. | 1990 | Biochemistry | pmid:1693856 |
| Starzl TE et al. | Kidney transplantation under FK 506. | 1990 | JAMA | pmid:1693970 |
| Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
| Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
| Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
| Maki N et al. | Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1695378 |
| Doe SE et al. | Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. | 1990 | Biochem. Soc. Trans. | pmid:1695581 |
| Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
| Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
| Isai H et al. | FK 506 and orthotopic liver transplantation in the rat. | 1990 | Transplant. Proc. | pmid:1699329 |
| Suzuki S et al. | In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. | 1990 | Heart Vessels | pmid:1699922 |
| Bierer BE et al. | Probing immunosuppressant action with a nonnatural immunophilin ligand. | 1990 | Science | pmid:1700475 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
| Wicker LS et al. | Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. | 1990 | Eur. J. Immunol. | pmid:1700753 |
| Sigal NH et al. | Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. | 1990 | Biochem. Pharmacol. | pmid:1700909 |
| Akutsu I et al. | [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. | 1990 | Arerugi | pmid:1705791 |
| Mochizuki M and Kawashima H | Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. | 1990 | Autoimmunity | pmid:1717007 |
| Ni M et al. | FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. | 1990 | Autoimmunity | pmid:1717008 |